ANIK Anika Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ANIK

Price (delayed)

$27.9

Market cap

$413.71M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.25

Enterprise value

$371.43M

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Anika Therapeutics partners with clinicians to understand what they need ...

Highlights
The company's gross profit rose by 11% YoY
Anika Therapeutics's debt has decreased by 7% YoY and by 2.1% QoQ
ANIK's equity is down by 25% year-on-year
Anika Therapeutics's quick ratio has decreased by 8% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.anikatherapeutics.com
Peers: MDT SYK STAA JNJ

Key stats

What are the main financial stats of ANIK
Market
Shares outstanding
14.83M
Market cap
$413.71M
Enterprise value
$371.43M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.99
Price to sales (P/S)
2.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.19
Earnings
Revenue
$169.26M
EBIT
-$81.25M
EBITDA
-$68M
Free cash flow
-$4.14M
Per share
EPS
-$5.25
Free cash flow per share
-$0.28
Book value per share
$14.04
Revenue per share
$11.52
TBVPS
$17.15
Balance sheet
Total assets
$263.74M
Total liabilities
$55.21M
Debt
$26.34M
Equity
$208.54M
Working capital
$130.5M
Liquidity
Debt to equity
0.13
Current ratio
5.59
Quick ratio
3.54
Net debt/EBITDA
0.62
Margins
EBITDA margin
-40.2%
Gross margin
62%
Net margin
-45.4%
Operating margin
-47.4%
Efficiency
Return on assets
-25.8%
Return on equity
-31.8%
Return on invested capital
-44.3%
Return on capital employed
-34.5%
Return on sales
-48%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ANIK stock price

How has the Anika Therapeutics stock price performed over time
Intraday
-1.45%
1 week
1.23%
1 month
8.77%
1 year
11.6%
YTD
23.12%
QTD
10.15%

Financial performance

How have Anika Therapeutics's revenue and profit performed over time
Revenue
$169.26M
Gross profit
$104.87M
Operating income
-$80.15M
Net income
-$76.83M
Gross margin
62%
Net margin
-45.4%
Anika Therapeutics's operating income has plunged by 182% YoY but it has increased by 9% from the previous quarter
Anika Therapeutics's operating margin has plunged by 163% YoY but it has increased by 10% from the previous quarter
The company's gross profit rose by 11% YoY
Anika Therapeutics's net margin has increased by 8% QoQ

Growth

What is Anika Therapeutics's growth rate over time

Valuation

What is Anika Therapeutics stock price valuation
ANIK P/E details
P/E
N/A
P/B
1.99
P/S
2.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.19
The company's EPS rose by 7% QoQ
ANIK's price to book (P/B) is 42% more than its last 4 quarters average of 1.4 and 11% more than its 5-year quarterly average of 1.8
ANIK's equity is down by 25% year-on-year
ANIK's P/S is 31% below its 5-year quarterly average of 3.5 but 15% above its last 4 quarters average of 2.1
The revenue has grown by 7% YoY

Efficiency

How efficient is Anika Therapeutics business performance
The ROIC has dropped by 180% year-on-year but it is up by 8% since the previous quarter
The company's return on sales has shrunk by 167% YoY but it rose by 9% QoQ

Dividends

What is ANIK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIK.

Financial health

How did Anika Therapeutics financials performed over time
The total assets has decreased by 22% YoY and by 2.5% QoQ
Anika Therapeutics's total liabilities has decreased by 10% YoY and by 5% from the previous quarter
Anika Therapeutics's debt is 87% lower than its equity
The debt to equity is up by 30% year-on-year
ANIK's equity is down by 25% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.